Osprey Medical, Inc.

Cardiora Pty Ltd.

Baker Heart and Diabetes Institute

Cardiac Dimensions, Inc.

Baker Medical Research Institute

Baker Idi Heart and Diabetes

David Martin Kaye

Tuan Minh Doan

Todd J Mortier

Matthew M Burns

Rodney L Houfburg

Daniel R Mans

Geetha Thanga Mariappan

Guy Krippner

Adam Lucas Bilney

Clifton A Alferness

James Edward Shapland

John Melmouth Power

Melissa Jane Byrne

Mark L Mathis

Nicholas J Ede

Robert W Trainor

Andrew N Hunter

Melissa Byrne

Steve Christov

A system for modulating delivery of a fluid medium includes an injector for injecting the fluid medium during an injection cycle, a delivery catheter including a conduit for delivering the fluid medium, a manifold disposed in a fluid medium flow path between the injector and the delivery catheter, and a pulsatile generator. The pulsatile generator is configured to apply a pulsatile force to the fluid medium defined by a plurality of duty cycles during the injection cycle, each of the duty cycles including a first pressure level and a second pressure level that is lower than the first pressure level.

Adjustable medium diverter

Devices, systems and methods for controlling, regulating, altering, transforming or otherwise modulating the delivery of a substance to a delivery site. The devices, systems and methods optimize the delivery of the substance to an intended site, such as a vessel, vascular bed, organ and/or other corporeal structures, while reducing inadvertent introduction or reflux substance to other vessels, vascular beds, organs, and/or other structures, including systemic introduction.

Devices and methods for modulating medium delivery

The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 &#x3bc;g/kg body weight/minute and 20 &#x3bc;g/kg body weight/minute.

Milrinone controlled-release formulation

The present invention relates to methods of treating subjects having heart failure with preserved ejection fraction (HFpEF) with a sustained-delivery formulation of cardiotonic 5-(pyridinyl)-2(1H)-pyridinone compounds.

Method of treating heart failure with preserved ejection fraction by administering milrinone

Systems and methods for modulating delivery of a fluid medium to a selected site within a patient's body are described. A system includes a syringe for injecting the fluid medium, a delivery catheter including a conduit for delivering the fluid medium from outside of the body to the selected site within the body, a diversion reservoir configured to receive a portion of the fluid medium, and a flow diverter assembly disposed in a fluid medium flow path between the syringe and the delivery catheter. The flow diverter assembly is configured to divert the portion of the fluid medium from the chamber of the syringe away from the delivery of the medium through the delivery catheter conduit during injecting with the syringe. The flow diverter assembly simultaneously increases fluid medium flow resistance with increasing pressure level of the fluid medium passing into the flow diverter assembly.

Uses of milrinone controlled-release formulation

A system for modulating delivery of a fluid medium to a selected site within a patient's body includes a syringe for injecting the fluid medium, a delivery catheter including a conduit for delivering the fluid medium from outside of the body to the selected site within the body, a medium reservoir configured to receive a portion of the fluid medium, and a flow diverter assembly disposed in a fluid medium flow path between the syringe and the delivery catheter. The syringe includes a chamber for receiving the fluid medium therein. The flow diverter assembly is configured to divert the portion of the fluid medium from the chamber of the syringe away from the delivery of the medium through the delivery catheter conduit during injecting with the syringe, and simultaneously increase medium fluid flow resistance with increasing pressure level of the fluid medium within the flow diverter assembly.

The present invention provides devices and methods for use in the perfusion of organs and anatomical regions. In one aspect the present method provides a percutaneously deliverable device for supporting a vessel in a human or animal subject including means for supporting the vessel during delivery of a fluid thereto or collection of a fluid therefrom. In another aspect the invention provides a method for delivery or collection of a fluid to or from an organ or anatomical region in a human or animal subject, the method including the step of supporting a vessel associated with the organ or anatomical region. The devices and methods may be used to deliver, remove or recirculate a therapeutic agent to an organ or anatomical region.

Devices and methods for perfusing an organ

A method of delivering a medicament to a limb of a patient body includes isolating a circulatory system of the limb from a circulatory system of the patient body, wherein the limb circulatory system is substantially all limb arteries and substantially all limb veins located between an isolation region and an end of the limb. A perfusion catheter is inserted into a limb artery in an antegrade position, while a collection catheter is inserted into a limb vein in a retrograde position. The blood flow of the limb circulatory system is then circulated by collecting the blood flow with the collection catheter and delivering the blood flow with the perfusion catheter. A medicament is perfused into the limb circulatory system with the perfusion catheter.

Systems and methods for limb treatment

Growing community of inventors

Beaumaris, Australia

David Martin Kaye